IPO News | Pilot Biotech's Hong Kong Stock IPO Prospectus Expires

The Zhitong Finance App learned that the Hong Kong Stock Prospectus submitted by Suzhou Pilot Biotechnology Co., Ltd. (Abbreviation: Pilot Biotech) on February 12, 2026 expired for 6 months. Huatai International was the sole sponsor when the statement was submitted.

According to the previous prospectus, Pilot Biotech is a leader in synthetic biology driven by technological innovation, and is committed to providing bio-based products that are green, sustainable, efficiently produced, and have outstanding cost advantages. As far as APIs and intermediates are concerned, according to insight, after achieving large-scale production of fluorfenicol in 2025, the company's market share for the same period was 24.5%, ranking second in the global fluorfenicol industry in terms of revenue for the nine months ended September 30, 2025; based on revenue for the nine months ended September 30, 2025 (including internal and external sales), the company's D-ethyl ester market share was 44.5%, ranking first in the global D-ethyl ester industry.